An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness of telaprevir in combination with
Peg-IFN-alfa-2a and ribavirin in stable liver transplant patients with chronic hepatitis C
virus (HCV) genotype 1.